Marleen van Loenen
Marleen van Loenen is Director Preclinical Development at Gadeta, a R&D company that focusses on the development of αβT cells modified with γδ T cell receptors to combat both hematological and solid cancers. Her experience in and enthusiasm for adoptive immunotherapy strategies started with her PhD at Leiden University Medical Center in TCR-gene transfer for hematological malignancies. Subsequently, she moved to Sanquin Amsterdam to study presence and fitness of tumor-reactive TILs within NSCLC, before joining Gadeta in 2017.
Michael Hudecek
Kip Cross
John Bridgeman
Fiona Thistlethwaite
Dan Ollendorf
Attilio Bondanza
Alasdair Rankin
Alasdair Rankin is Director of Research and Patient Experience at the blood cancer research charity Bloodwise. In addition to research, his responsibilities include Bloodwise’s policy and campaigning work, and its information and support services for people affected by blood cancer. Previously he was Director of Research at Diabetes UK from 2012 to 2015 where he developed the organisations current research strategy, including leading the establishment of diabetes Clinical Studies Groups and broadening engagement of people living with diabetes in research. He began working for research funders at Cancer Research UK, where he held various roles including leading the research funding operations team and establishing and leading the research strategy team, contributing to the development and implementation of Cancer Research UK’s 2011-15 research strategy. Alasdair is an elected Trustee of the National Cancer Research Institute.
